HHS Panel on Antiretroviral Guidelines for Adults and Adolescents Issues Statement on Use of Elvitegravir/Cobicistat/Tenofovir/Emtricitabine

The HHS Panel on Antiretroviral Guidelines for Adults and Adolescents recommends elvitegravir (EVG)/cobicistat (COBI)/tenofovir (TDF)/emtricitabine (FTC) as an alternative regimen for ART-naive patients. The fixed-dose combination product was recently approved by FDA. The Panel’s statement on use of EVG/COBI/TDF/FTC includes clinical trial and safety data on this combination product.